NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Traws Pharma, Inc. (TRAW) Stock Analysis

Traws Pharma, Inc. (TRAW) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TRAW

$0.38

−$0.00 (−0.19%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TRAW with… →

TRAW Key Statistics

As of Oct 21, 2026
Trading
Open
$0.38
Previous Close
$0.38
Day's Range
0.37–0.38
52-Week Range
0.36–3.23
Volume
83.64K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.53
Valuation
Market Cap
$5.78M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.71
Financials (FY)
Revenue (FY)
$2.79M+1,134.51%
Net Income (FY)
$9.17M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
15.37M
1-Year Return
−87.38%
Dividend and dates
Avg Volume
578.58K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TRAW closed at $0.38, −87.38% over 1 year.

Traws Pharma, Inc. (TRAW) has a market capitalization of $5.78M.

In fiscal 2025, TRAW reported revenue of $2.79M.

TRAW Stock Return by Calendar Year

Traws Pharma, Inc. (TRAW) 10-year return: what $10,000 became

1 year
$10,000 $1,262
−87.38%
5 years
$10,000 $42
−99.58%
10 years
$10,000 $0.26
−99.997%

If you had invested $10,000 in Traws Pharma, Inc. (TRAW) 10 years ago, at the close on October 21, 2016, it would have been worth $0.26 at the close on October 21, 2026: −99.997% in total, −65.23% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−66.73%
2025−87.27%
2024−52.64%
2023+15.38%
2022−74.51%
2021−63.83%
2020+23.68%
2019−81.99%
2018−90.62%
2017−33.92%
2016 (partial year)−31.63%

As of October 21, 2026.

TRAW Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.79M$9.17M328.7%
2024$226.00K−$166.52M−73,682.7%
2023$226.00K−$18.95M−8,384.1%
2022$226.00K−$18.96M−8,391.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.79M—−$17.88M$9.17M328.7%
2024$226.00K—−$24.91M−$166.52M−73,682.7%
2023$226.00K—−$20.30M−$18.95M−8,384.1%
2022$226.00K—−$19.63M−$18.96M−8,391.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Traws Pharma, Inc. (TRAW) carries a market capitalisation of $5.78M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 4.

Over the past 52 weeks the price has ranged from $0.36 to $3.23. The most recent close on file for TRAW is $0.38, dated October 21, 2026. That is $0.00 (−0.19%) against the previous close. The latest close sits 4.44% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.79M. Against the prior fiscal year total of $226.00K, that is a change of +1,134.51%. Net income for the same year was $9.17M. Earnings per share on a trailing basis come to −1.71.

Across the 4 fiscal years on file, revenue moves from $226.00K in 2022 to $2.79M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is −87.38%. Across 10 years the annualized return works out at −65.23%. The reported beta is 1.53. Daily returns over the trailing 10 years annualize to a volatility of 122.51%.

Growth & Income

The record shows no dividend for TRAW.

The strongest complete calendar year on file is 2020 at +23.68%; the weakest is 2018 at −90.62%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −66.73% year to date.

Peer Comparison

Traws Pharma, Inc. (TRAW) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Traws Pharma, Inc. TRAW $5.78M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Traws Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Traws Pharma, Inc.

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Visit website →